Discussing Obesity With Patients With Cancer
57% of respondents indicated that they discuss obesity with their patients after they are diagnosed with cancer, however nearly 40% of those polled indicated that they do not discuss the topic.
While the majority, 66%, of respondents said that they believe oncology care teams should advocate for policy changes in regards to weight management services and society factors related to obesity, 34% believe that this is not the job of the oncology care team.
A large portion, 84%, of readers who responded to the poll indicated that oncology care teams currently do not do enough to educate patients on the cancer risk associated with obesity--highlighting the need for ASCO's initiative.
The American Society of Clinical Oncology recently released a position statement on obesity and cancer.
While research related to obesity's effect on cancer is ongoing, it is clear that obesity is becoming a leading preventable cause of cancer (overtaking more well-known causes such as tobacco) and it's an important issue for oncologists to be informed about.
We asked Cancer Therapy Advisor readers to weigh in on how they handle the topic of obesity with their patients and the results were surprising.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC